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Abstract: Management of oral candidosis, most frequently caused by Candida albicans, is limited due
to the relatively low number of antifungal drugs and the emergence of antifungal tolerance. In this
study, the antifungal activity of a range of commercial essential oils, two terpenes, chlorhexidine and
triclosan was evaluated against C. albicans in planktonic and biofilm form. In addition, cytotoxicity of
the most promising compounds was assessed using murine fibroblasts and expressed as half maximal
inhibitory concentrations (IC50). Antifungal activity was determined using a broth microdilution
assay. The minimum inhibitory concentration (MIC) was established against planktonic cells cultured
in a range of concentrations of the test agents. The minimal biofilm eradication concentration (MBEC)
was determined by measuring re-growth of cells after pre-formed biofilm was treated for 24 h with the
test agents. All tested commercial essential oils demonstrated anticandidal activity (MICs from 0.06%
(v/v) to 0.4% (v/v)) against planktonic cultures, with a noticeable increase in resistance exhibited by
biofilms (MBECs > 1.5% (v/v)). The IC50s of the commercial essential oils were lower than the MICs,
while a one hour application of chlorhexidine was not cytotoxic at concentrations lower than the MIC.
In conclusion, the tested commercial essential oils exhibit potential as therapeutic agents against
C. albicans, although host cell cytotoxicity is a consideration when developing these new treatments.
Keywords: Candida albicans; oral candidosis; commercial essential oils; biocides; antifungal activity;
minimum inhibitory concentration; minimal biofilm eradication concentration; cytotoxicity
1. Introduction
Candida are commensal fungal microorganisms that can colonise the oral cavity, where they
are mainly found on the posterior part of the tongue and the oral mucosa. Changes in the oral
environment that lead to increased Candida growth can instigate oral candidosis [1]. The rising number
of immunocompromised and immunodeficient patients has resulted in an increased incidence of fungal
infections. To highlight this, Candida-related infections affect 65% of HIV positive individuals and over
80% of AIDS patients [2–4]. The higher life expectancy of the general population has also led to a rise in
denture wearing, with a concomitant increase in Candida-associated stomatitis [5–7]. Even though more
than 17 Candida species can cause human infection, oral candidosis are mainly caused by C. albicans [8].
In the mouth, Candida typically grows as biofilms, which are three-dimensional structures attached to
surfaces including human tissue or abiotic substrates (e.g., a denture). Biofilm cells are embedded in
a self-produced extracellular polymeric matrix and importantly often exhibit an elevated tolerance to
antimicrobial agents and host defences [5].
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Current therapies for oral candidosis include use of topical or systemic antifungal agents, such as
polyenes and azoles. Polyenes (e.g., nystatin and amphotericin B) are fungicidal through binding
to ergosterol in the fungal cell membrane and inducing cell membrane damage. Azoles, such as
fluconazole and miconazole, are fungistatic by inhibiting the enzyme lanosterol demethylase, involved
in ergosterol biosynthesis [9]. Importantly, the range of available antifungals are limited compared to
antibiotics [9] and coupled with the rise of Candida resistance, especially within biofilms, this has led to
an interest in the discovery of new antifungal compounds [10].
Essential oils are natural products produced by aromatic plants and are mainly composed
by terpenes and terpenoids [11]. Being lipophilic, these oils typically integrate into membrane
structures causing increased cell permeability, leaching of intracellular components and inactivation
of enzymes [12,13]. Essential oils can act against Candida by inhibiting ergosterol synthesis [14–18],
altering cell wall morphology [15,17–19], inhibiting enzymes involved in cell wall synthesis [18,20],
changing cell membrane permeability [21,22] and producing oxygen reactive species [23]. Furthermore,
essential oils can also interact with the mitochondrial membrane leading to cidal effects [11].
Antimicrobial, anti-aseptic, anti-inflammation and anti-oxidant activity of essential oils, alone and in
combination with commercial agents is well known [13,24–26]. However, limited knowledge exists
regarding essential oil activity against biofilms and also host cell cytotoxicity.
The aim of this study was therefore to investigate the antifungal potential of twelve commercial
essential oils and two terpenes (E-cinnamaldehyde and linalool) against C. albicans planktonic and
biofilm growth. The cytotoxicity of the most active commercial essential oils was established against
mouse fibroblasts. Antifungal activity of commercial essential oils was compared to chlorhexidine
(CHX) and triclosan. These two biocides have previously shown antimicrobial properties against
a wide range of oral pathogens and are frequent components in mouthwashes and toothpastes [27,28].
2. Results
2.1. Minimum Inhibitory Concentration (MIC) 80 and Minimal Lethal Concentration
The minimum inhibitory concentration (MIC) 80 of the test agents against C. albicans NCYC 1363
and C. albicans 135BM2/94 are shown in Table 1. The commercial essential oils that inhibited the
growth at the lowest concentrations were melissa and geraniol, while myrtle and sage had the lowest
fungistatic potential (p < 0.001).
Fungicidal activity was also expressed as the lowest concentration of antimicrobial agent
that killed the microorganism (minimal lethal concentration) (Table 2). All tested compounds,
with exception of triclosan, had minimal lethal concentrations against C. albicans at tested
concentrations. However, these lethal concentrations were generally higher than the previously
established MICs.
Table 1. Minimum inhibitory concentration 80 of commercial essential oils and biocides against
C. albicans NYCY 1363 and C. albicans 135BM2/94 in the planktonic form.
Antimicrobial
Minimum Inhibitory Concentration 80 [% (v/v)] [(g/L)]
C. albicans NYCY 1363 C. albicans 135BM2/94
Basil 0.1 (0.9) 0.1 (0.9)
Bergamot 0.3 (2.6) 0.3 (2.6)
Cinnamon 0.1 (1.0) 0.1 (1.0)
Citronella 0.1 (0.9) 0.1 (0.9)
Geranium 0.07 (0.6) 0.06 (0.5)
Lavender 0.2 (1.8) 0.1 (0.9)
Melissa 0.06 (0.5) 0.06 (0.5)
Myrtle 0.4 (3.5) 0.3 (2.7)
Peppermint 0.1 (0.9) 0.1 (0.9)
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Table 1. Cont.
Antimicrobial
Minimum Inhibitory Concentration 80 [% (v/v)] [(g/L)]
C. albicans NYCY 1363 C. albicans 135BM2/94
Sage 0.4 (3.7) 0.3 (2.7)
Spearmint 0.2 (1.6) 0.1 (1.1)
Tea tree oil 0.2 (1.8) 0.2 (1.8)
E-cinnamaldehyde 0.03 (0.3) 0.01 (0.1)
Linalool 0.1 (0.9) 0.1 (0.9)
CHX 2 × 10−3 (2.1 × 10−2) 5 × 10−3 (5.3 × 10−2)
Triclosan 5.66 × 10−4 (8.4 × 10−3) 5.89 × 10−4 (8.8 × 10−3)
Minimal inhibitory concentration 80 (MIC80) defined as the lowest concentration of the antimicrobial agent that led
to 80% reduction in absorbance compared to controls without agent. MIC values are in % (v/v) and in brackets are
the equivalent MIC values in (g/L).
Table 2. Minimal lethal concentration of commercial essential oils and biocides against C. albicans
NYCY 1363 and C. albicans 135BM2/94 in the planktonic growth mode.
Antimicrobial
Minimal Lethal Concentration [% (v/v)] [(g/L)]
C. albicans NCYC 1363 C. albicans 135BM2/94
Basil 0.5 (4.5) 0.5 (4.5)
Bergamot 0.5 (4.4) 0.5 (4.4)
Cinnamon 0.1 (1.0) 0.1 (1.0)
Citronella 0.1 (0.9) 0.1 (2.7)
Geranium 0.1 (0.9) 0.1 (0.9)
Lavender 0.5 (4.4) 0.3 (2.6)
Melissa 0.1 (0.9) 0.1 (0.9)
Myrtle 1 (8.8) 1 (8.8)
Peppermint 0.3 (2.7) 0.1 (0.9)
Sage 1 (9.2) 1 (9.2)
Spearmint 1 (9.2) 1 (9.2)
Tea tree oil 0.5 (4.5) 0.3 (2.7)
E-cinnamaldehyde 0.03 (0.3) 0.03 (0.3)
Linalool 0.3 (2.6) 0.3 (2.6)
CHX 2.5 × 10−3 (2.7 × 10−2) 5 × 10−3 (5.3 × 10−2)
Triclosan NA NA
Minimal lethal concentration was defined as the lowest concentration of the antimicrobial agent that killed C. albicans.
MLC values are in % (v/v) and in brackets are the equivalent MLC values in (g/L). NA = no antimicrobial activity
at tested concentrations.
2.2. Minimal Biofilm Eradication Concentration 80
The antifungal activity of biocides and commercial essential oils against C. albicans biofilms was
expressed as the minimal biofilm eradication concentration (MBEC) [29]. Most test agents were not
active against biofilms at tested concentrations and did not prevent regrowth after removal of the
antimicrobial (Table 3). The antimicrobials that exhibited an MBEC against both tested C. albicans
strains were melissa geranium, E-cinnamaldehyde and linalool (Table 3).
Table 3. Minimal biofilm eradication concentration 80 of commercial essential oils and biocides against
C. albicans NCYC 1363 and C. albicans 135BM2/94.
Antimicrobial
Minimal Biofilm Eradication Concentration 80 [% (v/v)] [(g/L)]
C. albicans NYCY 1363 C. albicans 135BM2/94
Basil NA NA
Bergamot NA NA
Cinnamon NA NA
Citronella NA NA
Geranium 2.5 (22.3) 2 (17.9)
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Table 3. Cont.
Antimicrobial
Minimal Biofilm Eradication Concentration 80 [% (v/v)] [(g/L)]
C. albicans NYCY 1363 C. albicans 135BM2/94
Lavender NA NA
Melissa 1.5 (13.3) 1.5 (13.3)
Myrtle NA NA
Peppermint NA NA
Sage NA NA
Spearmint NA NA
Tea tree oil NA NA
E-cinnamaldehyde 0.8 (8.4) 0.8 (8.4)
Linalool 1 (8.7) 1.5 (13.1)
CHX 0.07 NA
Triclosan >5 × 10−3 (7.45 × 10−2) >5 × 10−3 (7.45 × 10−2)
Minimal biofilm eradication concentration 80 (MBEC80) defined as the lowest antimicrobial concentration that
prevented at least 80% regrowth of Candida, after the biofilm was treated with antimicrobials for 24 h. MBEC values
are in % (v/v) and in brackets are the equivalent MBEC values in (g/L). NA = no antimicrobial activity at
tested concentrations.
2.3. Half Maximal Inhibitory Concentration (IC50) against Fibroblasts
The half maximal inhibitory concentration (IC50) CHX, cinnamon, E-cinnamaldehyde, geranium
and melissa on fibroblast proliferation after a 1 h and 24 h exposure was determined (Figure 1;
Table 4). The highest cytotoxicity occurred with E-cinnamaldehyde, followed by geranium (p < 0.0001),
which halved proliferation even at the lowest concentration tested. Indeed, a concentration of 0.003% (v/v)
E-cinnamaldehyde and 0.01% (v/v) geranium inhibited 50% of cell proliferation (Table 4). Melissa was the
least cytotoxic commercial essential oil, halving proliferation at 0.03% (v/v) (p < 0.0001). A 1 h exposure of
fibroblasts to cinnamon resulted in similar cytotoxicity as melissa but prolonged exposure led to higher
cytotoxicity (p < 0.0001). A 1 h application of CHX was cytotoxic only at the highest concentration tested
(IC50 of 0.01% (v/v)) which was higher than the MIC, while a 24 h exposure at 7× 10−4% (v/v) was
sufficient to halve fibroblast proliferation.
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Figure 1. Cytotoxicity of selected antimicrobials against murine fibroblasts. Fibroblast numbers 
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E-cinnamaldehyde 0.003 (0.03) 0.002 (0.02) 
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Half maximal inhibitory concentration (IC50) defined as the antimicrobial concentration that inhibits 
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Figure 1. Cytotoxicity of selected antimicrobials against murine fibroblasts. Fibroblast numbers
(normalised by the control (0% (v/v) antimicrobial) after a 1 h (red square) and 24 h application
(blue circle) of CHX (A); cinnamon (B); E-cinnamaldehyde (C); geranium (D) and melissa (E).
Table 4. Half maximal inhibitory concentration (IC50) against fibroblasts after 1 h and 24 h application
of the antimicrobial.
Antimicrobial
Half Maximal Inhibitory Concentration [% (v/v)] [(g/L)]
1 h 24 h
Cinnamon 0.03 (0.36) 0.01 (0.11)
Geranium 0.01 (0.08) 0.01 (0.07)
Melissa 0.03 (0.3) 0.03 (0.3)
E-cinnamaldehyde 0.003 (0.03) 0.002 (0.02)
CHX 0.01 (0.15) 7.32 × 10−4 (0.008)
Half maximal inhibitory concentration (IC50) defined as the antimicrobial concentration that inhibits the 50% of cell
proliferation com ared to controls without agent. IC50 values are in % (v/v) and in brackets are the equi ale t IC50
values in (g/L).
3. Discussion
Essential oils are natural products often extracted fro plants and they frequently exhibit
anti icrobial, anti-aseptic, anti-inflam atory and anti-oxidant activities. The primary aim of this research
was to evaluate the antifungal activity of 12 commercial essential oils against C. albicans. All tested
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commercial essential oils demonstrated antifungal activity against planktonic C. albicans, with MICs
ranging from 0.06% (v/v) to 0.4% (v/v) and MLCs from 0.1% (v/v) to 1% (v/v). Comparison of results
with those of other studies is problematic given differences in assay techniques [30,31]. In addition,
the botanical source, climate and environmental conditions, time of harvesting and extraction method can
affect both composition and antimicrobial activity of commercial essential oils [31–33].
The effect of plant origin on antimicrobial properties can be appreciated by comparing the activity
of cinnamon oil extracted from Cinnamomum zeylanicum leaves and Cinnamomum aromaticum leaves.
Both types of cinnamon oils are from the evergreen cinnamomum plant but Cinnamomum aromaticum
extract contains a higher amount of E-cinnamaldehyde, which could explain the higher
antifungal activity (MICs 0.0006% (v/v)–0.0096% (v/v)) [32] compared to the present study using
Cinnamomum zeylanicum (MIC 0.1% (v/v)) extract. The impact that the amount of E-cinnamaldehyde
has on antifungal properties of an essential oil was also evident in this study (MICs of 0.03% (v/v)
and 0.01% (v/v)). Geranium and melissa oils exhibited highest antifungal potential. Both commercial
oils contain geraniol and citronellol, which are antifungal [34] and likely responsible for the similar
antifungal activity of these oils (p > 0.90). However, the MIC of melissa oil was lower than that
previously reported [35,36]. This present study revealed antifungal effects for bergamot oil (MIC of
0.3% (v/v) and MLC of 0.5% (v/v)) which has previously only had limited attention. The MIC of
basil oil 0.1% (v/v) (0.9 g/L) was lower than previously reported, namely 0.5% (v/v) [30] and 0.312%
(v/v) [32] but comparable to the MIC (1250 µg/mL) found against a fluconazole resistant C. albicans
strain [15]. The main compound of basil and lavender oils is linalool, which previously has had MICs
ranging from 0.06% (v/v) to 0.12% (v/v) [37]. Comparing activity of pure linalool to those of basil
and lavender oils, the anticandidal activity of terpene was not significantly higher than that of basil
(p > 0.99). Tea tree oil had an MIC of 0.2% (v/v) and this was similar to that recorded by Hammer et al.
against C. albicans [38]. Sage oil exhibited MICs of 0.3% (v/v) (2.7 g/L) and 0.4% (v/v) (3.7 g/L),
which were comparable to the MIC of 2.78 g/L reported using a disk diffusion method [39] but lower
than the MIC of 1.32 mg/mL measured by broth microdilution assay [40]. Despite their differences in
composition, peppermint and spearmint oils had similar antifungal activities with MICs of 0.1% (v/v)
and 0.1% (v/v)–0.2% (v/v), respectively (p > 0.07). However, while the MICs of spearmint oil were
similar to those reported by Hammer et al. [30], the MIC of peppermint oil was higher than that found
by Those et al. [41]. Myrtle oil had the lowest antifungal potential, even though its MICs were lower
than those previously reported by Mahboubi et al. (MIC of 0.8–1.6% (v/v)) [42]. CHX and triclosan,
two biocides whose antimicrobial properties are widely recognised and both commonly added to
mouthwashes and toothpastes, were also evaluated in this study. Triclosan exhibited fungistatic
activity only at concentrations higher than those used in toothpaste formulations (0.3% (w/v) [43])
but did not exhibit fungicidal effects at tested concentrations.
The majority of agents had limited antibiofilm activity. Bacteria in biofilms can be between 10 and
1000 times more tolerant to antibiotics than their planktonic counterparts and similar findings have
been reported for Candida [44]. The mechanisms by which biofilm cells have elevated antimicrobial
tolerance are complex and likely multifactorial. These include altered gene expression following
surface attachment, reduced growth rates in biofilms, variable nutrient availability that induces
changes in phenotype and the presence of extracellular polymeric substances that impedes penetration
of agents into the biofilm [45]. Few studies have previously reported activity of commercial essential
oils or biocides against C. albicans biofilms [46,47]. In the present study, from melissa oil, geranium
oil, E-cinnamaldehyde and linalool all had anti-biofilm activity, whilst CHX only had anti-biofilm
activity against C. albicans NCYC 1363. A 3 min application of cinnamon (1 mg/mL) and citronella
(1 mg/mL) oils has been found to reduce biofilm cell numbers immediately after treatment but this
effect was not evident 48 h post treatment [46]. These results concur with the current study, where no
antibiofilm activity was noted for cinnamon and citronella oils after 24 h. An MBEC of tea tree oil of
12.5% (v/v) had previously been reported [47], which is a higher concentration (8% (v/v)) than tested
Pathogens 2018, 7, 15 7 of 12
in this study, as difficulties were encountered in forming a stable suspension of the oil-medium using
1% (v/v) Tween 80.
Few studies have investigated the cytotoxic effects of these oils. Cytotoxicity of CHX, cinnamon,
E-cinnamaldehyde, geranium and melissa oils had a dose- and time-dependent cytotoxicity. Overall,
the commercial essential oils halved fibroblast proliferation at concentrations lower than their MICs.
The IC50 values for E-cinnamaldehyde, geranium and cinnamon oils were actually 10-fold lower
than their MIC 80, while melissa oil had an MIC 80 of 0.06% (v/v) and an IC50 of 0.03% (v/v).
Although a different assay and cell type was used, the melissa oil results (IC50 0.3 g/L) were in
accordance with those of Paul et al. [48] who did not see a significant change in leukocytes viability
after 3 h treatment with 150 µg/mL melissa oil. Several studies have used E-cinnamaldehyde to inhibit
proliferation of cancer cells and reported IC50s ranging from 45.8 to 129.4 mM [49], higher than those
obtained in this study with fibroblasts (0.16–0.26 mM). Barros et al. found that at concentrations lower
than those evaluated in this study (5 µg/mL), Cinnamomum zeylanicum oil had cytoxicity towards
erythrocytes [50]. A 1 h exposure of fibroblasts to CHX (0.01% (v/v)) halved cell proliferation compared
to controls. However, this concentration was lower than the MICs (2.5 × 10−3% (v/v) and 5 × 10−3%
(v/v)) found in the current study. This finding was similar to the cytotoxic effect of CHX previously
reported using macrophages [51] and human alveolar bone cells [52]. Even if these results showed
that commercial essential oils were cytotoxic, it should be taken into account that cytotoxicity was
conducted in 2D culture, which is notably different from in vivo conditions. Further investigation on
mammalian cells could be performed in 3D culture or ex/in vivo models to better mimic the biological
structure of the tissues.
4. Materials and Methods
4.1. Essential Oils and Biocides Preparation
Twelve commercial essential oils (Essential Oils Direct Ltd., Oldham, UK) (Table 5), two terpenes
(E-cinnamaldehyde and linalool (Sigma-Aldrich, Gillingham, UK)), chlorhexidine digluconate (CHX)
(Sigma-Aldrich, Gillingham, UK) and triclosan (Irgasan from Sigma-Aldrich, Gillingham, UK)
were evaluated.
Table 5. List of commercial essential oils tested.
Plant Species Essential Oil Origin
Ocimum basilicum Basil oil Leaves
Citrus bergamia Bergamot FCF oil Peel
Cinnamomum zeylanicum Cinnamon leaf oil Leaves
Cymbopogon winterianus Citronella oil Aerial parts
Pelargonium graveolens Geranium oil Flowering herb
Lavandula angustifolia Lavender oil Flowering herb
Melissa officinalis Melissa oil Leaves and tops
Myrtus communis Myrtle oil Leaves
Mentha piperita Peppermint oil Whole plant
Salvia officinalis Sage oil Leaves
Mentha spicata Spearmint oil Aerial parts
Melaleuca alternifolia Tea tree oil Leaves and twigs
The commercial essential oils were tested at a range of concentrations against planktonic growth (2%
(v/v) to 0.007% (v/v) and biofilms (8% (v/v) to 0.125% (v/v)). All agents were prepared in Sabouraud
Dextrose Broth (SDB; Oxoid Ltd, Basingstoke, UK). To enhance dispersion of essential oils in the medium,
1% (v/v) Tween 80 (Sigma-Aldrich, Gillingham, UK) was added. In the case of biofilm studies, 0.015%
(w/v) Agar Bacteriological (LP0011 Oxoid) was added to SDB [53]. CHX was used in SDB at concentrations
between 0.04% (v/v) to 3.1 × 10−4% (v/v) and from 0.08% (v/v) to 6.2× 10−4% (v/v) for planktonic
and biofilm growth experiments, respectively. A 20% (w/v) stock solution of triclosan was prepared in
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Dimethyl Sulfoxide (DMSO) (Fisher Chemical, Loughborough, UK). Serial doubling dilutions of the stock
solution were prepared in SDB yielding final concentrations from 5.2× 10−6% (v/v) to 6.7× 10−4% (v/v)
and from 1.7× 10−4% (v/v) to 5× 10−3 (v/v) for planktonic and biofilm experiments, respectively.
4.2. Microorganisms
Candida albicans NYCY 1363 and C. albicans 135BM2/94 were used to assess antifungal activity
of commercial essential oils and biocides. Candida albicans 135BM2/94 is a clinical strain from the
School of Dentistry (Cardiff University), which has been described as a high invader of tissues [54].
Strains were subcultured onto Sabouraud Dextrose Agar (SDA) (CM0041 Oxoid) and grown at 37 ◦C
in an aerobic incubator for 24 h. A colony of C. albicans was inoculated in 20 mL of SDB and incubated
aerobically with shaking (150 rev/min) overnight at 37 ◦C. The overnight culture was prepared in SDB
to a turbidity equivalent to a 0.5 McFarland Standard and used for further experiments.
4.3. Minimum Inhibitory Concentration and Minimal Lethal Concentration
The minimum inhibitory concentration (MIC) and the minimal lethal concentration (MLC) were
determined using a broth microdilution assay. The method was adapted from that previously reported
by Malic et al. [29]. Briefly, 100 µL of antimicrobial and 100 µL of overnight culture diluted to
1 × 105 CFU/mL were added to the wells of 96-well microtitre plates (Thermo Fisher Scientific,
Hemel Hempstead, UK). Controls included Candida suspension cultured in SDB, with or without 0.5%
(v/v) of Tween 80. In addition, when triclosan was tested, SDB containing 1% (v/v) DMSO was used as
control. The plates were covered with the lids supplied by the manufacturer and sprayed with 3% (v/v)
of Triton 100-X (Sigma-Aldrich, Gillingham, UK) in pure ethanol to reduce condensation. The plates
were incubated aerobically at 37 ◦C with shaking at 110 rpm, for 24 h. Growth was estimated by
measuring turbidity of each well by spectrophotometric absorbance at 620 nm (Thermo Scientific™
Multiskan™ GO Microplate Spectrophotometer), shaking 3 s before the reading. The absorbance
readings were standardised against microbial-free controls. The minimal inhibitory concentration
80 (MIC 80) was defined as the lowest concentration of the antimicrobial agent that showed at least
80% reduction in absorbance compared to the control. The MLC was determined by plating selected
well contents (where no visible growth was evident) on to SDA and incubating for 24 h at 37 ◦C.
The MLC was defined as the lowest concentration of antimicrobial agent that killed the Candida
as shown by no colony growth on SDA. All concentrations were tested in quadruplicate and on
three separate occasions.
4.4. Minimal Biofilm Eradication Concentration 80
The minimal biofilm eradication concentration (MBEC) method was adapted from Malic et al.
(2013) [29]. Briefly, a 96-well microtitre plate containing 200 µL of an overnight culture diluted
at 1 × 105 CFU/mL was incubated for 48 h at 37 ◦C without agitation to allow biofilm formation.
Controls included Candida suspension cultured in SDB, with or without 1% (v/v) of Tween 80 and
0.015% (w/v) Agar Bacteriological. When triclosan was tested, SDB containing 8% (v/v) DMSO
was also used as control. After 48 h, the SDB was removed and the microtitre plate inverted onto
tissue paper to remove residual medium. The biofilm was washed three times with 100 µL of PBS.
One hundred µL of test agent was added to the biofilm and the plate incubated statically for 24 h at
37 ◦C. After incubation, test agent was removed and the biofilm washed twice with 100 µL of PBS.
Two hundred µL of SDB was added to each well and the biofilm disrupted by repeated pipetting.
The three replicates were then pipetted into a microcentrifuge tube which was then centrifuged for
3 min at 3000 rev/min (Hettich Universal Mikro 12–24, Hettich, Tuttlingen, Germany). The supernatant
containing residual test agent was discarded and the microorganisms resuspended in fresh SDB and
three wells of a 96-well plate were inoculated with the suspension. The turbidity of the suspension
was measured by spectrophotometer absorbance at 620 nm prior to and after incubation for 24 h at
37 ◦C with shaking at 110 rev/min. The minimal biofilm eradication concentration 80 (MBEC80) was
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defined as the lowest antimicrobial concentration that prevented at least 80% regrowth of Candida.
All experiments were conducted on three separate occasions.
4.5. Half Maximal Inhibitory Concentration
Mouse fibroblasts (NIH 3T3; Sigma-Aldrich, Gillingham, UK) were cultured in Dulbecco
Modified Eagle Medium (DMEM, Sigma) supplemented with 10% (v/v) foetal bovine serum (FBS)
(Gibco, BRL), 1% (v/v) penicillin/streptomycin (Sigma-Aldrich, Gillingham, UK) and 1% (v/v)
L-glutamine (Sigma-Aldrich, Gillingham, UK). Serial doubling dilutions of commercial essential
oils and biocides were prepared in the fibroblast culture medium at final concentrations ranging
from 0.25% to 0.007% (v/v) for the commercial essential oils and from 0.04% to 3 × 10−4% (v/v)
for chlorhexidine. Fibroblasts were harvested using trypsin EDTA (EDTA 0.25% (w/v), Trypsin 0.53
mM, Thermo Fisher Scientific, Hemel Hempstead, UK) and diluted to a density of 5 × 105 cells/mL.
One-hundred µl of the cell suspension was used to inoculate a 96-well plate (5 × 104 cells per well)
which was then incubated at 37 ◦C and 5% CO2 for 1.5 h. A 100-µL volume of the antimicrobial was
then added. After 1 and 24 h, the medium was removed and the cells washed twice with 100 µL of PBS.
Three hundred µL of DMEM containing 10% (v/v) of alamarBlue (AlamarBlue Cell Viability Reagent,
Invitrogen) was added to each well and the plate incubated for 1.5 h. Fluorescence was read with
a Synergy HT plate reader (BioTek® Instruments, Winooski, VT, USA) with excitation and emission
wavelengths of 545 nm and 590 nm, respectively. The half maximal inhibitory concentration (IC50)
was defined as the antimicrobial concentration that inhibited 50% cell proliferation compared to the
control (i.e., DMEM without antimicrobial agent). Each condition was studied in triplicate and on
three separate occasions.
4.6. Statistical Analysis
Statistical analysis was performed using GraphPad Prism Version 7.0 (GraphPad Software, Inc.,
La Jolla, CA, USA). Data were presented as arithmetic mean ± SD. The difference between treatments
was statistically analysed using one-way analysis of variance (ANOVA) followed by Tukey multiple
comparisons test. Statistically significant differences were set at p < 0.05.
5. Conclusions
This study showed that all the twelve commercial essential oils, two terpenes and triclosan
and CHX had antifungal activity against planktonic C. albicans. Six of these compounds (CHX,
cinnamon, E-cinnamaldehyde, linalool, geranium and melissa) were also active against C. albicans
biofilms, which are usually challenging to effectively inhibit. Cytotoxicity screening revealed that the
commercial essential oils halved fibroblast proliferation at concentrations lower than those required
to inhibit C. albicans growth. Further investigation on the effect of these agents against mammalian
cells is however warranted before any in vivo application. The antifungal potential of these essential
oils could be a future therapeutic for topical candidosis as an option to overcome emerging antifungal
drug resistance.
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